Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors

Zurawa-Janicka,Dorota; Kobiela,Jarosław; Galczynska,Natalia; Stefaniak,Tomasz; Lipinska,Barbara; Lachinski,Andrzej; Skorko-Glonek,Joanna; Narkiewicz,Joanna; Proczko-Markuszewska,Monika; Sledzinski,Zbigniew

doi:10.3892/or.2012.1988

Changes in expression of human serine protease HtrA1, HtrA2 and HtrA3 genes in benign and malignant thyroid tumors

Authors:
- Dorota Zurawa-Janicka
- Jarosław Kobiela
- Natalia Galczynska
- Tomasz Stefaniak
- Barbara Lipinska
- Andrzej Lachinski
- Joanna Skorko-Glonek
- Joanna Narkiewicz
- Monika Proczko-Markuszewska
- Zbigniew Sledzinski
View Affiliations

Affiliations: Department of Biochemistry, University of Gdansk, 80-822 Gdansk, Poland, Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk, 80-952 Gdansk, Poland
Published online on: August 23, 2012 https://doi.org/10.3892/or.2012.1988
Pages: 1838-1844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human HtrA proteins are serine proteases involved in essential physiological processes. HtrA1 and HtrA3 function as tumor suppressors and inhibitors of the TGF-β signaling pathway. HtrA2 regulates mitochondrial homeostasis and plays a pivotal role in the induction of apoptosis. The aim of the study was to determine whether the HtrA proteins are involved in thyroid carcinogenesis. We used the immunoblotting technique to estimate protein levels of HtrA1, HtrA2, long and short variants of HtrA3 (HtrA3-L and HtrA3-S) and TGF-β1 in tissues of benign and malignant thyroid lesions, and control groups. We found that the levels of HtrA2 and HtrA3-S were higher in thyroid malignant tumors compared to normal tissues and benign tumors. The HtrA3-L level was increased in malignant tumor tissues compared to benign tumor tissues and control tissues from patients with benign lesions, and elevated in normal tissues from patients with thyroid carcinoma compared to normal tissues from patients with benign lesions. We also compared levels of HtrA proteins in follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC) and found that these types of carcinoma differed in the expression of HtrA3-S and HtrA1. These results indicate the implication of HtrA proteins in thyroid carcinogenesis suggest that HtrA3 variants may play different roles in cancer development, and that the increased HtrA3-L levels in thyroid tissue could be correlated with the development of malignant lesions. The TGF-β1 levels in tumor tissues were not significantly altered compared to control tissues.

View Figures

View References

1	Fassnacht M, Kreissl MC, Weismann D and Allolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther. 123:117–141. 2009. View Article : Google Scholar : PubMed/NCBI
2	Urken ML: Management of well-differentiated thyroid cancer in 2010: perspectives of a head and neck surgical oncologist. Endocr Pract. 16:903–912. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kapur U and Wojcik EM: Follicular neoplasm of the thyroid-vanishing cytologic diagnosis? Diagn Cytopathol. 35:525–528. 2007. View Article : Google Scholar : PubMed/NCBI
4	Freitas BC and Cerutti JM: Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol Cell Endocrinol. 321:77–85. 2010. View Article : Google Scholar : PubMed/NCBI
5	Clausen T, Southan C and Ehrmann M: The HtrA family of proteases implications for protein composition and cell fate. Mol Cell. 10:443–455. 2002.PubMed/NCBI
6	Zurawa-Janicka D, Skorko-Glonek J and Lipińska B: HtrA proteins as targets in therapy of cancer and other diseases. Expert Opin Ther Targets. 14:665–679. 2010. View Article : Google Scholar : PubMed/NCBI
7	Chien J, Campioni M, Shridhar V and Baldi A: HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets. 9:451–468. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zumbrumm J and Treub B: Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett. 398:187–192. 1996. View Article : Google Scholar : PubMed/NCBI
9	Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricala C, Amantea A, Noonan DM, Albini A, et al: The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene. 21:6684–6688. 2002. View Article : Google Scholar : PubMed/NCBI
10	Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH and Shridhar V: A candidate tumor suppressor HtrA1 is down-regulated in ovarian cancer. Oncogene. 23:1636–1644. 2004. View Article : Google Scholar : PubMed/NCBI
11	Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, et al: Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest. 116:1994–2004. 2006. View Article : Google Scholar : PubMed/NCBI
12	Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J and Lipińska B: Changes in expression of human HtrA1, HtrA2 and HtrA3 genes in ovarian cancer. Clin Biochem. 41:561–569. 2008.
13	Bowden MA, Di Nezza-Cossens LA, Jobling T, Salamonsen LA and Nie G: Serine proteases HtrA1 and HtrA3 are down-regulated with increasing grades of human endometrial cancer. Gynecol Oncol. 103:253–260. 2006. View Article : Google Scholar : PubMed/NCBI
14	Narkiewicz J, Lapińska-Szumczyk S, Zurawa-Janicka D, Skorko-Glonek J, Emerich J and Lipińska B: Expression of human HtrA1, HtrA2, HtrA3 and TGF-β1 genes in primary endometrial cancer. Oncol Rep. 21:1529–1537. 2009.
15	Esposito V, Campioni M, De Luca A, Spugnini EP, Baldi F, Cassandro R, Mancini A, Vincenzi B, Groeger A, Caputi M and Baldi A: Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res. 26:3455–3459. 2006.PubMed/NCBI
16	Kotliarow Y, Steed ME, Christopher N, Walling J, Su Q, Center A, Heiss J, Rosenblum M, Mikkelsen T, Zenklusen JC and Fine HA: High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alterations and allelic imbalances. Cancer Res. 66:9428–9436. 2006. View Article : Google Scholar : PubMed/NCBI
17	Baldi A, Mottolese M, Vincenzi B, Campioni M, Mellone P, Di Marino M, di Crescenzo VG, Visca P, Menegozzo S, Spugnini EP, et al: The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomisc. 9:1069–1077. 2008. View Article : Google Scholar : PubMed/NCBI
18	Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J, Yano M, Tsuchiya A, Ueta Y, Soam A, Kanda H, et al: HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins. Development. 131:1041–1053. 2004.PubMed/NCBI
19	Launay S, Maubert E, Lebeurrier A, Tennstaedt A, Campioni M, Docagne F, Gabriel C, Dauphinot L, Potier MC, Ehrmann M, et al: HtrA1-dependent proteolysis of TGF-β controls both neuronal maturation and development survival. Cell Death Differ. 15:1408–1416. 2008.PubMed/NCBI
20	Inman GJ: Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev. 21:93–99. 2011.
21	Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DoBois G, Lazebnik Y, Zevros AS, Fernandes-Alnemri T and Alnemri ES: Identification of Omi/HtrA2 as mitochondrial apoptotic serine protease that disrupts inhibitors of apoptosis protein-caspase interaction. J Biol Chem. 277:432–438. 2002. View Article : Google Scholar : PubMed/NCBI
22	Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, Savopoulos J, Gray CW, Creasy CL, Dingwall C and Downward J: The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem. 277:439–444. 2002. View Article : Google Scholar : PubMed/NCBI
23	Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A, Burke R, Wrobel C, et al: HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis protein. J Biol Chem. 277:445–454. 2002. View Article : Google Scholar : PubMed/NCBI
24	Srinivasula SM, Gupta S, Datta P, Zhang Z, Hegde R, Cheong N, Fernandes-Alnemri T and Alnemri ES: Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem. 278:31469–31472. 2003. View Article : Google Scholar : PubMed/NCBI
25	Yang QH, Church-Hajduk R, Ren J, Newton ML and Du Ch: Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 17:1487–1496. 2003. View Article : Google Scholar : PubMed/NCBI
26	Seong YM, Choi JY, Park HJ, Kim KJ, Ahn SG, Seong GH, Kim IK, Kang S and Rhim H: Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP. J Biol Chem. 279:37588–37596. 2004. View Article : Google Scholar : PubMed/NCBI
27	Trencia A, Fiory F, Maitan MA, Vito P, Barbagallo AP, Perfetti A, Miele C, Ungaro P, Oriente F, Cilenti L, et al: Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea15. J Biol Chem. 279:46566–46572. 2004. View Article : Google Scholar : PubMed/NCBI
28	Cilenti L, Soundarapandrian MM, Kyriasis GA, Stratico V, Singh S, Gupta S, Bonventre JV, Alnemri ES and Zervos AS: Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem. 279:50295–50301. 2004. View Article : Google Scholar : PubMed/NCBI
29	Liu Z, Li H, Derouet M, Berezkin A, Sasazuki T, Shirasawa S and Rosen K: Oncogenic Ras inhibits anoikis of intestinal epithelial cells by preventing the release of a mitochondrial pro-apoptotic protein Omi/HtrA2 into the cytoplasm. J Biol Chem. 281:14738–14747. 2006. View Article : Google Scholar : PubMed/NCBI
30	Simpson CD, Anyiwe K and Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185. 2008. View Article : Google Scholar : PubMed/NCBI
31	Nie GY, Li Y, Minoura H, Batten L, Ooi GT, Findley JK and Salamonsen LA: A novel serine protease of the mammalian HtrA family is up-regulated in mouse uterus coinciding with plancentation. Mol Hum Reprod. 9:279–290. 2003. View Article : Google Scholar : PubMed/NCBI
32	Nie GY, Li Y, Hale K, Okada H, Manuelpillai U, Wallace EM and Salamonsen LA: Serine protease HtrA3 is closely associated with human plancetal development and is elevated in pregnancy serum. Biol Reprod. 74:366–374. 2006. View Article : Google Scholar
33	Nie G, Hale K, Li Y, Manuelpillai U, Wallace EM and Salamonsen LA: Distinct expression and localization of serine protease HtrA1 in human endometrium and first-trimester plancenta. Dev Dyn. 235:3448–3455. 2006. View Article : Google Scholar : PubMed/NCBI
34	Nie GY, Hampton A, Li Y, Findlay JK and Salamonsen LA: Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem J. 371:39–48. 2003. View Article : Google Scholar : PubMed/NCBI
35	Tocharus J, Tsuchiya A, Kajikawa M, Ueta Y, Oka C and Kawaichi M: Developmentally regulated expression of Morse HtrA3 and its role as an inhibitor of TGF-β signaling. Dev Growth Differ. 46:257–274. 2004.PubMed/NCBI
36	Beleford D, Rattan R, Chien J and Shridhar V: High-temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. J Biol Chem. 285:12011–12027. 2010. View Article : Google Scholar : PubMed/NCBI
37	Beleford D, Liu Z, Rattan R, Quagliuolo L, Boccellino M, Baldi A, Maguire J, Staub J, Molina J and Shridhar V: Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Cancer Res. 16:398–409. 2010.PubMed/NCBI
38	Lipinska B, Zylicz M and Georgopoulos C: The HtrA (DegP) protein, essential for Escherichia coli survival at elevated temperatures, is an endoprotease. J Bacteriol. 172:1791–1797. 1990.PubMed/NCBI
39	Laemmli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
40	Pound JD: Immunochemical protocols. Methods in Molecular Biology. 80. Walker JM: Humana Press; Totowa, NJ: 1998, View Article : Google Scholar
41	Zurawa-Janicka D, Kobiela J, Stefaniak T, Wozniak A, Narkiewicz J, Limon J, Wozniak M and Lipinska B: Changes in expression of HtrA1 and HtrA2 serine proteases during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster. Acta Biochem Polon. 55:9–19. 2008.PubMed/NCBI
42	Hu XY, Xu YM, Chen XC, Ping H, Chen ZH and Zeng FQ: Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. Acta Pathol Microbiol Immunol Scand. 114:893–898. 2006. View Article : Google Scholar : PubMed/NCBI
43	Lee SH, Lee JW, Kim HS, Kim SY, Park WS, Kim SH, Lee JY and Yoo NJ: Immunohistochemical analysis of Omi/HtrA2 expression in stomach cancer. APMIS. 111:586–590. 2003. View Article : Google Scholar : PubMed/NCBI
44	Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcionomas subclasses. Proc Natl Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
45	Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, et al: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 167:1763–1775. 2005. View Article : Google Scholar : PubMed/NCBI
46	Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
47	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subclasses in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
48	Handkiewecz-Junak D, Czarniecka A and Jarzab B: Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 322:8–28. 2010. View Article : Google Scholar : PubMed/NCBI
49	Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, Quagliuolo L, Baldi A and Shridhar V: Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol. 29:4177–4187. 2009. View Article : Google Scholar : PubMed/NCBI